Status: retired, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 2150838016 | Efalizumab 125mg/vial lyophilized powder for injection (product) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 2154139018 | Efalizumab 125mg/vial lyophilised powder for injection | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 2155162014 | Efalizumab 125mg/vial lyophilized powder for injection | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 2536699016 | Efalizumab 100mg/mL powder+solvent for injection solution | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Efalizumab 125mg/vial lyophilized powder for injection | Is a | Product containing efalizumab (medicinal product) | false | Inferred relationship | Some | ||
| Efalizumab 125mg/vial lyophilized powder for injection | Has active ingredient | Efalizumab (substance) | false | Inferred relationship | Some | ||
| Efalizumab 125mg/vial lyophilized powder for injection | Has active ingredient | Immunosuppressant (substance) | false | Inferred relationship | Some | ||
| Efalizumab 125mg/vial lyophilized powder for injection | Has manufactured dose form | Injection | false | Inferred relationship | Some | ||
| Efalizumab 125mg/vial lyophilized powder for injection | Is a | Product manufactured as parenteral dose form (product) | false | Inferred relationship | Some | ||
| Efalizumab 125mg/vial lyophilized powder for injection | Has manufactured dose form | Injection powder | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Raptiva 125mg/vial lyophilized powder for injection | Is a | False | Efalizumab 125mg/vial lyophilized powder for injection | Inferred relationship | Some |
Reference Sets
Concept inactivation indicator reference set
FHIR